ArticleThe Journal of pediatrics2017
Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
Article in The Journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis.The Journal of international medical research · 2020Pooled it
- The prediction of disease chronicity when immune thrombocytopenia is first diagnosed.Translational pediatrics · 2026Article
- Advances in management of pediatric chronic immune thrombocytopenia: a narrative review.Journal of Yeungnam medical science · 2023Article
- A New Immunosuppressive Therapy for Very Severe Aplastic Anemia in Children with Autoantibodies.Current medical science · 2022Article
- Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.Blood · 2020Review
- Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?Clinical hematology international · 2019Article
- Updated international consensus report on the investigation and management of primary immune thrombocytopenia.Blood advances · 2019Article
- Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?Haematologica · 2019Review
- Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura.Experimental and therapeutic medicine · 2019Article
- Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo assess initial and long-term outcome of children with persistent/chronic idiopathic thrombocytopenic purpura (ITP) treated with 4 infusions of rituximab and three 4-day cycles of dexamethasone (4R+3Dex) including cohorts with most benefit and/or treatment associated toxicity. STUDY
designAll pediatric patients with ITP at Weill-Cornell who received 4R+3Dex were included in this retrospective study. Duration was median time from first rituximab infusion to treatment failure. Patient cohort included 33 children ages 1-18 years with persistent/chronic ITP; 19 were female, 10 of whom were adolescents. Every patient had failed more than 1 and usually several ITP treatments.
resultsChildren were treated with rituximab, 375 mg/m
conclusionsDurable unmaintained ITP remission after 4R+3Dex was seen almost exclusively in female adolescents with <24 months duration of ITP. This provides a new therapeutic paradigm for a subpopulation with hard-to-treat chronic ITP. The pathophysiology of ITP underlying this distinction requires further elucidation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.